New splice variant isoform of vegf
Номер патента: EP4237434A1
Опубликовано: 06-09-2023
Автор(ы): Christopher MONTEMAGNO, Gilles PAGES, Jerome Durivault
Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Cote dAzur
Опубликовано: 06-09-2023
Автор(ы): Christopher MONTEMAGNO, Gilles PAGES, Jerome Durivault
Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Cote dAzur
Реферат: The present invention relates notably to a new isolated splice variant isoform of VEGF having pro-angiogenic and pro-lymphangiogenic activity, said isolated isoform comprising an amino acid sequence having at least 80%, preferably at least 95%, identity to the amino acid sequence of SEQ ID NO:l, preferably is VEGF222/NF and consists of SEQ ID NO:l.
Isolated molecule of nucleic acid, which codes fused polypeptide that is able to bind vessel endotheliocytes growth factor (vegf), fused polypeptide, copied expressive vector, method for production of fused polypeptide, trap of vegf, pharmaceutical composition, method for treatment and set for treatment of vegf-mediated disease or condition
Номер патента: RU2376373C2. Автор: Николас Дж. ПАПАДОПУЛОС,Томас Дж. ДЕЙЛИ,Джеймс П. ФЭНДЛ. Владелец: Ридженерон Фармасьютикалз, Инк.. Дата публикации: 2009-12-20.